Clinical Trials
17 trialsNCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
NCT01498458 2022-06-10
PazoX
GBG Forschungs GmbH
Phase 1 Completed
NCT01466972 2020-07-08
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
University of California, San Francisco
Phase 2 Completed
NCT01392352 2020-02-13
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT01639911 2019-07-22
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
University of Illinois at Chicago
Phase 1 Completed
NCT00509587 2018-08-08
Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01394211 2018-07-26
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
University of Arizona
Phase 2 Terminated
NCT00615524 2018-01-12
Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer
GlaxoSmithKline
Phase 2 Withdrawn
NCT01012362 2017-12-28
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00388076 2017-11-17
Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
GlaxoSmithKline
Phase 1 Completed
NCT00722293 2017-11-13
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00347919 2016-02-25
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00450879 2015-03-25
Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00849472 2014-03-04
Treatment With Pazopanib for Neoadjuvant Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01060514 2013-10-30
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
Northwestern University
Phase 1 Terminated
NCT00558103 2013-02-04
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
GlaxoSmithKline
Phase 2 Completed